Literature DB >> 3733279

The absolute and relative bioavailability of dipyridamole from different preparations and the in vitro-in vivo comparison.

B Terhaag, F Donath, G Le Petit, K Feller.   

Abstract

The in vitro liberation and the bioavailability (BV) of dipyridamole (D) in three different brands (A, B, C) were determined in a three way cross-over study on 12 healthy subjects. Also, the pharmacokinetics of D given intravenously was investigated. The in vitro liberation of B is only to be achieved by repeated touching. The tmax for the preparations, expressed as mean +/- s mean amounts as follows: A: 0.8 +/- 0.06; B: 1.1 +/- 0.1; C: 0.8 +/- 0.09 hours and is in the case of B significantly different (p less than 0.05) from the others. The cmax values (A: 1.01 +/- 0.25; B: 1.16 +/- 0.15; C: 1.51 +/- 0.3 mumol X l-1) and the AUC values (A: 3.8 +/- 0.9; B: 3.1 +/- 0.5; C: 3.8 +/- 0.7 mumol X h X l-1) are not different. The absolute BV of D is 27 +/- 5.5% (range: 11-44%) independent of the used brand. In 4 subjects a second tmax at the 4th-6th hour is to be observed irrespective of the way of dosing. An enterohepatic circulation is assumed. It is concluded that the determination of the in vitro liberation is a necessary and useful parameter, but cannot be used alone for characterization of the BV in every case, as e.g., for problem drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3733279

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  3 in total

1.  Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media.

Authors:  Edmund S Kostewicz; Ulrich Brauns; Robert Becker; Jennifer B Dressman
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

2.  Reverse screening approach to identify potential anti-cancer targets of dipyridamole.

Authors:  Shu-Min Ge; Dong-Ling Zhan; Shu-Hua Zhang; Li-Qiang Song; Wei-Wei Han
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

3.  BCRP transports dipyridamole and is inhibited by calcium channel blockers.

Authors:  Yi Zhang; Anshul Gupta; Honggang Wang; Lin Zhou; R Robert Vethanayagam; Jashvant D Unadkat; Qingcheng Mao
Journal:  Pharm Res       Date:  2005-11-01       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.